Loading
A phase 3 trial of Encorafenib, Binimetinib, Pembrolizumab in melanoma, run by Pfizer, active and no longer recruiting.
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma is a phase 3 interventional study registered as NCT04657991 by Pfizer, with 257 participants enrolled, started 2021-01-15 and due to reach its primary completion in 2026-10-30. Interventions recorded: Encorafenib, Binimetinib, Pembrolizumab. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Binimetinib, Encorafenib, BRAF V600-mutant melanoma, Melanoma.
Shares Binimetinib, Encorafenib, BRAF V600-mutant melanoma, Advanced melanoma (unresectable stage III and stage IV).
Shares Encorafenib, Pfizer (incl. Seagen), Pembrolizumab, Small-molecule kinase inhibitors.
Shares BRAF V600-mutant melanoma, Advanced melanoma (unresectable stage III and stage IV), Pfizer (incl. Seagen), Melanoma.
Shares Binimetinib, Encorafenib, BRAF V600-mutant melanoma.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma, Pembrolizumab, Immune checkpoint inhibitors.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma, Pembrolizumab, Immune checkpoint inhibitors.
Shares BRAF V600-mutant melanoma, Advanced melanoma (unresectable stage III and stage IV), Melanoma, Small-molecule kinase inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/